Subtyping for Polycystic Ovary Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to use machine learning to identify different types of Polycystic Ovary Syndrome (PCOS) and examine their effects on fertility treatments and metabolism. It focuses on various groups with distinct features, such as high male hormones, being overweight, and elevated levels of SHBG, LH, or AMH. Women with PCOS who experience irregular periods, signs of high male hormones, or polycystic ovaries on ultrasound may be suitable candidates.
As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research that could personalize PCOS treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this classification method is safe for subtyping PCOS?
Research has shown that different types of Polycystic Ovary Syndrome (PCOS) have unique characteristics and safety profiles. This study explores what past research indicates about each type.
For the HA-PCOS group, characterized by high levels of male hormones, symptoms can include acne and extra hair growth. This condition can affect fertility and pregnancy, but past studies have not shown specific evidence of serious safety issues from treatments aimed at reducing male hormone levels.
In the OB-PCOS group, marked by being overweight or obese, studies have found that PCOS can lead to problems like insulin resistance, type 2 diabetes, and heart risks. Managing weight and metabolic health is important, but research has not shown clear evidence of serious side effects from treatments for these issues.
The SHBG-PCOS type involves high levels of a protein called sex hormone-binding globulin (SHBG). New research suggests SHBG could help manage PCOS, but there is limited data on treatment safety. Since SHBG is a marker and not a treatment target, direct safety concerns are less likely.
Lastly, the LH-PCOS group, with high levels of luteinizing hormone (LH), does not show negative effects on egg development and ovulation in recent studies. This suggests that treatments targeting LH levels may be safe.
Overall, while PCOS types have certain health risks, past research has not provided strong evidence of serious safety issues with treatments for these specific types. However, those considering participation should discuss any concerns with their healthcare providers.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it uses a machine-learning model to classify polycystic ovary syndrome (PCOS) into distinct subtypes, which could revolutionize how PCOS is understood and treated. Unlike current treatments that often take a one-size-fits-all approach, this method targets specific features of each subtype, such as hyperandrogenism, obesity, high serum SHBG, and elevated LH and AMH levels. By tailoring treatment to the unique characteristics of each subtype, this approach could lead to more effective and personalized care for those with PCOS.
Who Is on the Research Team?
Zi-jiang Chen
Principal Investigator
Center for Reproductive Medicine, Shandong University
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo a telephone interview and physical examination to gather baseline data
Follow-up
Prospective 6.5-year follow-up data will be collected to assess various outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Long-term follow-up
Find a Clinic Near You
Who Is Running the Clinical Trial?
Shandong University
Lead Sponsor